Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - naltrexone hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - naltrexone hydrochloride, quantity: 50 mg - tablet, film coated - excipient ingredients: titanium dioxide; powdered cellulose; lactose monohydrate; microcrystalline cellulose; iron oxide black; crospovidone; iron oxide yellow; colloidal anhydrous silica; iron oxide red; hypromellose; macrogol 4000; magnesium stearate - naltrexone gh is indicated for use within a comprehensive treatment programme for alcohol dependence. naltrexone gh is also indicated as adjunctive therapy in the maintenance of formerly opioid-dependent patients who have ceased the use of opioids such as diamorphine (heroin) and morphine.

Malta - English - Medicines Authority

accord healthcare limited - naltrexone hydrochloride - film-coated tablet - naltrexone hydrochloride 50 mg - other nervous system drugs

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - naltrexone hydrochloride - film-coated tablet - naltrexone hydrochloride 50 mg - other nervous system drugs

United States - English - NLM (National Library of Medicine)

specgx llc - naltrexone hydrochloride (unii: z6375yw9sf) (naltrexone - unii:5s6w795cqm) - naltrexone hydrochloride 50 mg - naltrexone hydrochloride tablets are indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids. naltrexone hydrochloride tablets have not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions. naltrexone is contraindicated in: 1. patients receiving opioid analgesics. 2. patients currently dependent on opioids, including those currently maintained on opiate agonists (e.g., methadone) or partial agonists (e.g., buprenorphine). 3. patients in acute opioid withdrawal (see warnings ). 4. any individual who has failed the naloxone challenge test or who has a positive urine screen for opioids. 5. any individual with a history of sensitivity to naltrexone or any other components of this product. it is not known if there is any cross-sensitivity with naloxone or the phenanthrene containing opioids. naltrexone is a pure opioid antagonist. it does not lead to physical or psychological depend

United States - English - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - naltrexone hydrochloride (unii: z6375yw9sf) (naltrexone - unii:5s6w795cqm) - naltrexone hydrochloride 50 mg - naltrexone hydrochloride tablets are indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids. naltrexone has not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions. naltrexone is contraindicated in: - patients receiving opioid analgesics. - patients currently dependent on opioids, including those currently maintained on opiate agonists [e.g., methadone or laam (levo- alpha-acetyl-methadol)]. - patients in acute opioid withdrawal (see warnings ). - any individual who has failed the naloxone challenge test or who has a positive urine screen for opioids. - any individual with a history of sensitivity to naltrexone or any other components of this product. it is not known if there is any cross-sensitivity with naloxone or the phenanthrene containing opioids. - any individual with acute hepatitis or liver failure. naltrexone is a pure opioid antagonist. it does not lead to physical or p

United States - English - NLM (National Library of Medicine)

precision dose inc. - naltrexone hydrochloride (unii: z6375yw9sf) (naltrexone - unii:5s6w795cqm) - naltrexone hydrochloride 50 mg - naltrexone hydrochloride tablets are indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids. naltrexone has not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions. naltrexone is contraindicated in: - patients receiving opioid analgesics. - patients currently dependent on opioids, including those currently maintained on opiate agonists [e.g., methadone or laam (levo- alpha-acetyl-methadol)]. - patients in acute opioid withdrawal (see warnings ). - any individual who has failed the naloxone challenge test or who has a positive urine screen for opioids. - any individual with a history of sensitivity to naltrexone or any other components of this product. it is not known if there is any cross-sensitivity with naloxone or the phenanthrene containing opioids. - any individual with acute hepatitis or liver failure. naltrexone is a pure opioid antagonist. it does not lead to physical or p

United States - English - NLM (National Library of Medicine)

avkare - naltrexone hydrochloride (unii: z6375yw9sf) (naltrexone - unii:5s6w795cqm) - naltrexone hydrochloride 50 mg - naltrexone hydrochloride tablets usp are indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids. naltrexone hydrochloride tablets usp have not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions. naltrexone hydrochloride is contraindicated in: - patients receiving opioid analgesics. - patients currently dependent on opioids, including those currently maintained on opiate agonists (e.g., methadone) or partial agonists (e.g., buprenorphine). - patients in acute opioid withdrawal (see warnings ). - any individual who has failed the naloxone challenge test or who has a positive urine screen for opioids. - any individual with a history of sensitivity to naltrexone hydrochloride or any other components of this product. it is not known if there is any cross-sensitivity with naloxone or the phenanthrene containing opioids. naltrexone hydrochloride is a pure opioid antagonist. it does not lead to physical or psychological dependence. tolerance to the opioid antagonist effect is not known to occur.

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - naltrexone hydrochloride (unii: z6375yw9sf) (naltrexone - unii:5s6w795cqm) - naltrexone hydrochloride 50 mg - naltrexone hydrochloride tablets are indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids. naltrexone has not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions. naltrexone is contraindicated in: - patients receiving opioid analgesics. - patients currently dependent on opioids, including those currently maintained on opiate agonists [e.g., methadone or laam (levo- alpha-acetyl-methadol)]. - patients in acute opioid withdrawal (see warnings ). - any individual who has failed the naloxone challenge test or who has a positive urine screen for opioids. - any individual with a history of sensitivity to naltrexone or any other components of this product. it is not known if there is any cross-sensitivity with naloxone or the phenanthrene containing opioids. - any individual with acute hepatitis or liver failure. naltrexone is a pure opioid antagonist. it does not lead

United States - English - NLM (National Library of Medicine)

tagi pharma inc. - naltrexone hydrochloride (unii: z6375yw9sf) (naltrexone - unii:5s6w795cqm) - naltrexone hydrochloride 50 mg - naltrexone hydrochloride tablets usp are indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids. naltrexone hydrochloride tablets usp have not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions. naltrexone hydrochloride is contraindicated in: - patients receiving opioid analgesics. - patients currently dependent on opioids, including those currently maintained on opiate agonists (e.g., methadone) or partial agonists (e.g., buprenorphine). - patients in acute opioid withdrawal (see warnings ). - any individual who has failed the naloxone challenge test or who has a positive urine screen for opioids. - any individual with a history of sensitivity to naltrexone hydrochloride or any other components of this product. it is not known if there is any cross-sensitivity with naloxone or the phenanthrene containing opioids. naltrexone hydrochloride is a pure opioid antagonist. it does not